| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Molecular Oncology, Markers, Clinical Correlates |
Department of Orthopedic Surgery, Sapporo Medical University School of Medicine, Hokkaido 060-8543 [M. K., T. W., T. A., S. K., S. N., S. I.]; Department of Oral Pathology, Hokkaido University School of Dentistry, Hokkaido 060-8586 [M. S., F. H., F. M.]; and Laboratory of Pathology, Cancer Institute, Hokkaido University School of Medicine, Hokkaido 060-8638 [F. O.], Japan
To investigate the clinical significance of vascular endothelial growth factor (VEGF) in osteosarcoma, we immunohistochemically stained biopsy specimens of 27 primary osteosarcomas using an antibody against VEGF and evaluated the correlation between the expression of VEGF and local density of CD34-positive microvessels, clinicopathological variables, and survival of patients. VEGF staining was positive in 17 tumors (63.0%) in which the density of CD34-positive microvessels was significantly higher than that in VEGF-negative 10 tumors (P < 0.05). In terms of clinicopathological variables, there was no correlation between the expression of VEGF and histological subtype, stage, or response to neoadjuvant chemotherapy, or, strikingly, to the development of pulmonary metastasis (89% of VEGF-positive tumors versus 10% of VEGF-negative tumors; P < 0.0003). Moreover, patients with a VEGF-positive tumor were poorer in both disease-free survival (P < 0.001) and overall survival (P < 0.03) compared to those with a VEGF-negative tumor. These findings strongly suggest that VEGF expression in untreated osteosarcoma is predictive of pulmonary metastasis and poor prognosis in patients who underwent aggressive therapy and also provide the basis for a therapeutic strategy targeting angiogeneic property of osteosarcoma.
This article has been cited by other articles:
|
|
 |
|
  N. Boku, A. Ohtsu, F. Nagashima, K. Shirao, and W. Koizumi Relationship between Expression of Vascular Endothelial Growth Factor in Tumor Tissue from Gastric Cancers and Chemotherapy Effects: Comparison between S-1 alone and the Combination of S-1 plus CDDP Jpn. J. Clin. Oncol., August 2, 2007; (2007) hym057v1. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Boku, A. Ohtsu, S. Yoshida, K. Shirao, Y. Shimada, I. Hyodo, H. Saito, Y. Miyata, and Gastrointestinal Oncology Study Group of Japan Cli Significance of Biological Markers for Predicting Prognosis and Selecting Chemotherapy Regimens of Advanced Gastric Cancer Patients between Continuous Infusion of 5-FU and a Combination of 5-FU and Cisplatin Jpn. J. Clin. Oncol., May 23, 2007; (2007) hym015v1. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Q.-C. Yang, B.-F. Zeng, Y. Dong, Z.-M. Shi, Z.-M. Jiang, and J. Huang Overexpression of Hypoxia-Inducible Factor-1{alpha} in Human Osteosarcoma: Correlation with Clinicopathological Parameters and Survival Outcome Jpn. J. Clin. Oncol., February 1, 2007; 37(2): 127 - 134. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. K. Heck Jr., T. D. Peabody, and M. A. Simon Staging of Primary Malignancies of Bone CA Cancer J Clin, November 1, 2006; 56(6): 366 - 375. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Kreuter, R. Bieker, S. S. Bielack, T. Auras, H. Buerger, G. Gosheger, H. Jurgens, W. E. Berdel, and R. M. Mesters Prognostic Relevance of Increased Angiogenesis in Osteosarcoma Clin. Cancer Res., December 15, 2004; 10(24): 8531 - 8537. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M A Ghanem, G J van Steenbrugge, M K Sudaryo, R B Mathoera, J M Nijman, and T. H van der Kwast Expression and prognostic relevance of vascular endothelial growth factor (VEGF) and its receptor (FLT-1) in nephroblastoma J. Clin. Pathol., February 1, 2003; 56(2): 107 - 113. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. F. Dvorak Vascular Permeability Factor/Vascular Endothelial Growth Factor: A Critical Cytokine in Tumor Angiogenesis and a Potential Target for Diagnosis and Therapy J. Clin. Oncol., November 1, 2002; 20(21): 4368 - 4380. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Tsuchiya, Y. Kanazawa, M. E. Abdel-Wanis, N. Asada, S. Abe, K. Isu, T. Sugita, and K. Tomita Effect of Timing of Pulmonary Metastases Identification on Prognosis of Patients With Osteosarcoma: The Japanese Musculoskeletal Oncology Group Study J. Clin. Oncol., August 15, 2002; 20(16): 3470 - 3477. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. P. Gibbs Jr., K. Weber, and M. T. Scarborough Malignant Bone Tumors J. Bone Joint Surg. Am., November 1, 2001; 83(11): 1728 - 1745. [Full Text] [PDF]
|
|
|
|
 |
|
 C. Chao, T. Al-Saleem, J. J. Brooks, A. Rogatko, W. G. Kraybill, and B. Eisenberg Vascular Endothelial Growth Factor and Soft Tissue Sarcomas: Tumor Expression Correlates With Grade Ann. Surg. Oncol., April 1, 2001; 8(3): 260 - 267. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. T.-P. Poon, S.-T. Fan, and J. Wong Clinical Implications of Circulating Angiogenic Factors in Cancer Patients J. Clin. Oncol., February 15, 2001; 19(4): 1207 - 1225. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
